Clinical Scenario

This protocol applies to asymptomatic individuals with congenital long QT syndrome who have documented QT interval prolongation — with or without an identified pathogenic mutation. Despite the absence of symptoms, the prolonged QTc represents an actionable finding that warrants a structured management approach.

Clinical Goals

The primary objective is to reduce the risk of future arrhythmic events. In patients considered for certain pharmacological additions, a measurable reduction in QTc interval on oral testing is used to confirm adequacy of response before long-term therapy is initiated.

Treatment Approach — Partial Overview

Management combines a structured set of general precautionary measures with pharmacological therapy centred on non-selective beta-blockade; in a specific genetic subtype, an additional agent targeting the relevant ion channel may be incorporated. The complete genotype-guided algorithm — including sequencing, criteria, and monitoring targets — is available in the full protocol.

References

DOI: 10.1093/eurheartj/ehac262

Asymptomatic patient with or without pathogenic mutation and QT prolongation
ICD implantation may be considered in asymptomatic LQTS patients with high-risk profile (according to the 1-2-3 LQTS Risk calculator) in addition to genotype-specific medical therapies (mexiletine in LQT3 patients).
Avoid QT-prolonging drugs.
Avoid and correct electrolyte abnormalities.
Avoid genotype-specific triggers for arrhythmias.
Beta-blockers, ideally non-selective beta-blockers (nadolol or propranolol), are recommended in LQTS patients with documented QT interval prolongation, to reduce risk of arrhythmic events.
Mexiletine is indicated in LQT3 patients with a prolonged QT interval.
It is advisable to perform oral testing to verify that the QTc shortens 40 ms before prescribing chronic treatment.

View source ↗

Treatment of Congenital Long QT Syndrome — Asymptomatic Patient with QT Interval Prolongation

References